DFP-10917 for Acute Myeloid Leukemia

Recruiting at 37 trial locations

Overseen By Tapan Kadia, MD

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Delta-Fly Pharma, Inc.

Disqualifiers: Cardiac dysfunction, High WBC, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 28-day cycles

450 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment, DFP-10917, for individuals with acute myeloid leukemia (AML) that has returned or did not respond after two to four previous treatments. The study compares DFP-10917 to other standard treatments, either less intensive options or more intense chemotherapy, depending on participants' prior treatments. Individuals with AML who have tried several treatment plans and still have the disease might be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants access to a potentially groundbreaking treatment.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, there is a requirement to wait at least 2 weeks after cytotoxic treatments or 5 half-lives for noncytotoxic treatments before starting the study drug. Hydroxyurea is allowed before and during early treatment cycles if needed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that DFP-10917, administered as a continuous IV drip for 14 days, is generally safe for individuals with acute leukemias, including acute myeloid leukemia (AML). Studies have found that patients tolerate the treatment well at a dose of 6 mg/m² per day. Some patients might experience side effects, but these are usually manageable. If significant side effects occur, the dose can be reduced to 4 mg/m² per day for future treatment cycles, maintaining safety and tolerability.

For those considering participation in a trial with DFP-10917, this information suggests the treatment is reasonably safe. However, discussing any concerns with a healthcare provider is always important. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for AML?

Researchers are excited about DFP-10917 for treating Acute Myeloid Leukemia (AML) because it offers a unique approach compared to traditional therapies. Unlike standard treatments such as cytarabine and various chemotherapy combinations, DFP-10917 is administered through a continuous infusion over 14 days, allowing for a more consistent delivery of the drug. This treatment focuses on a new mechanism that may target leukemia cells more effectively, potentially offering benefits in terms of fewer side effects and improved patient outcomes. Additionally, the dosing schedule provides a balance between treatment and rest periods, which could enhance patient comfort and adherence.

What evidence suggests that this trial's treatments could be effective for acute myeloid leukemia?

Research has shown that DFP-10917, which participants in this trial may receive, could be a promising treatment for acute myeloid leukemia (AML). Some studies found that this treatment, given as a continuous infusion, can be safely administered and has been effective in patients with AML. Observations indicate that DFP-10917 may help some patients achieve remission, meaning their symptoms reduce or disappear, especially those who have tried several other treatments. Early findings suggest it could be a good option for managing AML when other treatments haven't worked. Overall, researchers are actively studying DFP-10917 for its potential to fight this difficult-to-treat disease. ^{1 2 3 4 6}

Who Is on the Research Team?

Tapan Kadia, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults over 18 with AML that's come back or hasn't responded after 2-4 previous treatments. They should be relatively healthy (ECOG Performance Status of 0, 1, or 2) and have good kidney, liver, and blood test results. People with active leukemia in the brain or uncontrolled illnesses can't join.

Inclusion Criteria

Adequate clinical laboratory values

I do not have any uncontrolled illnesses.

Signed informed consent prior to the start of any study specific procedures

Exclusion Criteria

My heart's pumping ability is reduced (LVEF ≤40%).

White blood cell (WBC) count >15,000/μL

Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either DFP-10917 or a control regimen (Non-Intensive or Intensive Reinduction) based on prior treatments and clinical condition

28-day cycles

Continuous monitoring during treatment cycles

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 years

What Are the Treatments Tested in This Trial?

Interventions

• DFP-10917

Trial Overview

The study compares DFP-10917 given as a continuous IV infusion for two weeks followed by two weeks off against standard reinduction therapies chosen based on what patients had before. It's a phase III trial where participants are randomly assigned to one of these treatments.

How Is the Trial Designed?

Group I: Experimental Experimental Treatment 1 Intervention

DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles

Group II: Control Active Control 9 Interventions

Non-Intensive: * LoDAC: 20 mg SC BID 10 days * Azacitidine: 75 mg/m²/day SC 7 days(or 5+2) * Decitabine: CIV 20 mg/m²x5 days * Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10. Intensive: * High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m² * FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 \& G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida) * MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr \& cytarabine 1g/m² IV 6hr. * CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3. * Intermediate DAC: cytarabine 20 mg/m² IV dailyx5

Who Is Running the Clinical Trial?

Delta-Fly Pharma, Inc.

Lead Sponsor

Trials

5

Recruited

610+

Published Research Related to This Trial

Acute myelogenous leukemia (AML) is more prevalent in older adults, and traditional chemotherapy may not be suitable for them due to various biological factors, highlighting the need for tailored treatments.

Promising new treatment options for older AML patients include CPX-351, a liposomal formulation of cytarabine and daunorubicin, and other therapies like alvocidib, clofarabine, tipifarnib, decitabine, and azacitidine, which are being evaluated for their efficacy and safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development of therapeutic agents for older patients with acute myelogenous leukemia. Hourigan, CS., Karp, JE.[2021]

In a study of 46 acute myeloid leukemia (AML) patients, a combination of Chinese medicine and chemotherapy significantly improved blood counts and immune cell levels after 2 months of treatment, indicating enhanced recovery post-remission.

The treatment led to a maximum disease-free survival (DFS) of 123 months, with a 3-year survival rate of 64.15% and a 5-year survival rate of 51.19%, suggesting that this integrative approach may be effective for long-term management of AML.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Observation on treatment of post-remission acute myeloid leukemia patients by lingxiong piaoling powder and longchan cigu decoction]. Su, EY., Chen, HS., Han, YM.[2017]

In a study of 100 patients with acute myeloid leukaemia not responsive to first induction chemotherapy (PIF-AML), the overall survival (OS) rates were low, with only 23% alive after a median follow-up of 11 months, highlighting the poor prognosis of this condition.

Allogeneic stem cell transplantation (Allo-SCT) significantly improved the 12-month OS probability to 60% compared to 35% for those who did not undergo the procedure, emphasizing the critical need for urgent donor searches and effective pre-transplant treatment strategies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. Lazzarotto, D., Candoni, A., Nadali, G., et al.[2017]

The traditional classification of acute myeloid leukemia (AML) is inadequate for predicting treatment outcomes and does not account for significant subgroups, such as elderly patients or those with AML following myelodysplastic syndrome (MDS).

A new classification model divides AML into MDS-related (MDR-AML) and true de novo (TDN-AML) groups, which have distinct genetic characteristics and treatment responses, suggesting that this revised model could improve therapeutic strategies and outcomes for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Revised classification of acute myeloid leukemia. Head, DR.[2013]

Older patients with acute myeloid leukemia (AML) have a lower success rate with standard chemotherapy compared to younger patients, highlighting a need for tailored treatment approaches.

The review emphasizes that age-related changes in drug metabolism and toxicity can significantly impact the efficacy of antileukemic agents, suggesting that modifications to current therapies may improve outcomes for elderly patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. Kaur, I., Constance, JE., Kosak, KM., et al.[2017]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT01702155

NCT01702155 | Phase I/II Study of DFP-10917 in Patients ...

This study will determine the safety and efficacy of DFP-10917 in patients with AML or ALL. The Phase I dose-escalation portion of the study will determine the ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/30668890/

Phase 1/2 study of DFP-10917 administered by continuous ...

DFP-10917 as a 14-day continuous intravenous infusion at a dose of 6 mg/m 2 /day can be administered safely and appears to be effective in patients with ...

3.

ashpublications.org

ashpublications.org/blood/article/142/Supplement%201/5976/504952/Ongoing-Phase-III-Randomized-Trial-of-Salvage-DFP

Ongoing Phase III Randomized Trial of Salvage DFP-10917 ...

A Phase III, randomized, controlled study to compare the rate and duration of CR in patients with AML R/R to 2-4 prior induction regimens.

4.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06382168

DFP-10917 in Combination With Venetoclax in Relapsed ...

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia.

5.

ucihealth.org

ucihealth.org/clinical-trials/uci-24-48

Phase I/II Study of DFP-10917 in Combination ...

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia.

6.

acsjournals.onlinelibrary.wiley.com

acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31923

Phase 1/2 study of DFP‐10917 administered by continuous ...

The current phase 1/2 study investigated the safety, maximum tolerated dose, and evidence of antileukemic activity for DFP-10917 administered by ...